SEC Form 4 · accession 0001161697-17-000255
CATALYST PHARMACEUTICALS, INC. · CPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick J McEnany
Officer — President and CEO · Director
Period of report
May 22, 2017
Accepted (ET)
May 22, 2017 · 2:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001369568
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, par value $0.001 per share | May 22, 2017 | M | 31,250 | $1.04 | A | 4,451,026 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants to Purchase Common StockF1 | $1.04 | May 22, 2017 | X | 31,250 | D | May 30, 2012 | May 30, 2017 | Common Stock | 31,250 | 0 | D |
Explanation of responses
- F1Securities were sold as units, each consisting of one share of the Issuer's common stock and one five-year warrant to purchase one share of the Issuer's common stock, at a price of $0.80 per unit.